Dr. John Cush RheumNow
4 years 3 months ago
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022
https://t.co/j4LJPZFqzY https://t.co/ABAbm3axSG
Dr. John Cush RheumNow
4 years 3 months ago
Polymyalgia rheumatica immunological puzzle further illustrated
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022.
https://t.co/Miab1eiHZ6 https://t.co/n9IjPwqG2t
Dr. John Cush RheumNow
4 years 3 months ago
Watch this 4 minute video on Belimumab use in pregnancy featuring Dr. Kathryn Dao ( @KDAO2011 )
https://t.co/8uRUIVURHF https://t.co/lbYwHFFJit
Dr. John Cush RheumNow
4 years 3 months ago
Studies suggest that the IL-23/Th-17 axis is one of the key pathways involved in the pathogenesis of plaque psoriasis and psoriatic arthritis. Learn more here: https://t.co/oj00pk4dLT
Sponsored by Janssen @JanssenUS https://t.co/4IhyX6sF7p
Dr. John Cush RheumNow
4 years 3 months ago
Miss this week's TNR? Watch the playback.
https://t.co/LSlw939Vj2 https://t.co/K62afKWz95
Dr. John Cush RheumNow
4 years 3 months ago
Can we stop RA before it happens?
Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent RA occurring in at-risk individuals.
https://t.co/vU4tRr7UJh https://t.co/cikU9pwaiT
CDC is tracking multiple reported U.S. monkeypox cases, and monitoring cases in persons in countries without endemic monkeypox and with no known travel links to an endemic area; current epidemiology suggests person-to-person community spread.
Dr. John Cush RheumNow
4 years 3 months ago
Price of a newly launched drug increased from $2115 per year in 2008 to $180 007 per year in 2021. In 2008 only 9% of drug cost >$150k/yr; this rose to 47% by 2021. Greater increases seen w/ biologics, rare disease and nononcology drugs https://t.co/JaGzNqCxdF
Dr. John Cush RheumNow
4 years 3 months ago
Gout Undertreatment Persists
Despite updated gout management guidelines from EULAR and BSR, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.
https://t.co/qW7ZaXbnx3 https://t.co/ZBKIjuQp10
Dr. John Cush RheumNow
4 years 3 months ago
Watch: RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
https://t.co/Lp25lP6ZZY https://t.co/wd5GCbaCLR
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media…
